Lamberto Andreotti, Chief Operating Officer of Bristol-Myers Squibb, presented at the Deutsche Bank Healthcare Conference on May 7, 2008. He discussed Bristol-Myers Squibb's strong Q1 2008 performance with 9% underlying sales growth and improved margins. He highlighted several drugs like Plavix, Abilify, and Orencia that showed significant sales increases. Andreotti also outlined Bristol-Myers Squibb's approach to productivity improvements through redesigning supply chain operations, restructuring customer models, and R&D transformation to generate $1.5 billion in savings.
Private Equity Trends in Central & Eastern EuropePete Chatziplis
Trends in strategic and private equity M&As in Central & Eastern Europe. Presented at the mindspeaker/Eastern European Think & Act Tank conference in New York as part of a series of presentations from dignitaries from Central & Eastern Europe, regarding business opportunities in the region.
Private Equity Trends in Central & Eastern EuropePete Chatziplis
Trends in strategic and private equity M&As in Central & Eastern Europe. Presented at the mindspeaker/Eastern European Think & Act Tank conference in New York as part of a series of presentations from dignitaries from Central & Eastern Europe, regarding business opportunities in the region.
BioSyent (RX.V or BIOYF) is a rapidly growing pharmaceutical company that acquires or in-licenses proven drugs and markets them in Canada. Their business model is to build and sell a portfolio of products that have a peak penetration potential that is too small for major pharmaceutical companies. What has fascinated us about BioSyent is their ability to consistently grow revenue and earnings. In fact, their pharmaceutical sales have grown sequentially for the past 12 quarters, which is very rare in the microcap space. In 2012 they announced several new products that they have added to their portfolio plus they have a nice pipeline of additional products that we expect to further fuel their growth. In the most recent quarter they grew revenues 60% and net income 79% year/year. Listen to CEO Rene Goehrum as he tells the story.
BioSyent (RX.V or BIOYF) is a rapidly growing pharmaceutical company that acquires or in-licenses proven drugs and markets them in Canada. Their business model is to build and sell a portfolio of products that have a peak penetration potential that is too small for major pharmaceutical companies. What has fascinated us about BioSyent is their ability to consistently grow revenue and earnings. In fact, their pharmaceutical sales have grown sequentially for the past 12 quarters, which is very rare in the microcap space. In 2012 they announced several new products that they have added to their portfolio plus they have a nice pipeline of additional products that we expect to further fuel their growth. In the most recent quarter they grew revenues 60% and net income 79% year/year. Listen to CEO Rene Goehrum as he tells the story.
what is the future of Pi Network currency.DOT TECH
The future of the Pi cryptocurrency is uncertain, and its success will depend on several factors. Pi is a relatively new cryptocurrency that aims to be user-friendly and accessible to a wide audience. Here are a few key considerations for its future:
Message: @Pi_vendor_247 on telegram if u want to sell PI COINS.
1. Mainnet Launch: As of my last knowledge update in January 2022, Pi was still in the testnet phase. Its success will depend on a successful transition to a mainnet, where actual transactions can take place.
2. User Adoption: Pi's success will be closely tied to user adoption. The more users who join the network and actively participate, the stronger the ecosystem can become.
3. Utility and Use Cases: For a cryptocurrency to thrive, it must offer utility and practical use cases. The Pi team has talked about various applications, including peer-to-peer transactions, smart contracts, and more. The development and implementation of these features will be essential.
4. Regulatory Environment: The regulatory environment for cryptocurrencies is evolving globally. How Pi navigates and complies with regulations in various jurisdictions will significantly impact its future.
5. Technology Development: The Pi network must continue to develop and improve its technology, security, and scalability to compete with established cryptocurrencies.
6. Community Engagement: The Pi community plays a critical role in its future. Engaged users can help build trust and grow the network.
7. Monetization and Sustainability: The Pi team's monetization strategy, such as fees, partnerships, or other revenue sources, will affect its long-term sustainability.
It's essential to approach Pi or any new cryptocurrency with caution and conduct due diligence. Cryptocurrency investments involve risks, and potential rewards can be uncertain. The success and future of Pi will depend on the collective efforts of its team, community, and the broader cryptocurrency market dynamics. It's advisable to stay updated on Pi's development and follow any updates from the official Pi Network website or announcements from the team.
If you are looking for a pi coin investor. Then look no further because I have the right one he is a pi vendor (he buy and resell to whales in China). I met him on a crypto conference and ever since I and my friends have sold more than 10k pi coins to him And he bought all and still want more. I will drop his telegram handle below just send him a message.
@Pi_vendor_247
how can i trade pi coins for Bitcoin easily.DOT TECH
Pi is not launched yet on any exchange, it is not sellable, but you can actually exchange your I network coins to other currencies. By selling your pi network coins to investors and holders of the coins.
How can I find a pi network investor
Lol, you don't need to find a investor all you have to do is to sell your pi coins to a vendor [ buys from miners and resells to the holders]
I will leave the whatsapp contact of my personal pi network vendor to trade Pi coins with.
@Pi_vendor_247
#pi network
#pi
#passive income
#legit
#bitcoin
Currently pi network is not tradable on binance or any other exchange because we are still in the enclosed mainnet.
Right now the only way to sell pi coins is by trading with a verified merchant.
What is a pi merchant?
A pi merchant is someone verified by pi network team and allowed to barter pi coins for goods and services.
Since pi network is not doing any pre-sale The only way exchanges like binance/huobi or crypto whales can get pi is by buying from miners. And a merchant stands in between the exchanges and the miners.
I will leave the telegram contact of my personal pi merchant. I and my friends has traded more than 6000pi coins successfully
Tele-gram
@Pi_vendor_247
Even tho Pi network is not listed on any exchange yet.
Buying/Selling or investing in pi network coins is highly possible through the help of vendors. You can buy from vendors[ buy directly from the pi network miners and resell it]. I will leave the telegram contact of my personal vendor.
@Pi_vendor_247
Yes. Selling pi coins in Indonesia is the same as selling pi coins in any other country. Because there is only one way selling pi coins is possible. And this is through pi vendors or merchants
Who is a pi vendor.
A pi vendor is someone who buys and sell pi coins to investors looking forward to hold pi till mainnet launch.
I will leave the whatsapp contact of my personal pi vendor here, highly recommendable
@Pi_vendor_247
PD ARRAY THEORY FOR INTERMEDIATE (1).pdfJerrySMaliki
Dealing range is the new trading range formed after buyside and sale side
is taken.
PD array is the distinction between Premium to Discount inside that
dealing range including the array list inside the two ranges.
Dealing range is the new trading range formed after buyside and sale side
is taken.
PD array is the distinction between Premium to Discount inside that
dealing range including the array list inside the two ranges. Dealing range is the new trading range formed after buyside and sale side
is taken.
PD array is the distinction between Premium to Discount inside that
dealing range including the array list inside the two ranges. Dealing range is the new trading range formed after buyside and sale side
is taken.
PD array is the distinction between Premium to Discount inside that
dealing range including the array list inside the two ranges. Dealing range is the new trading range formed after buyside and sale side
is taken.
PD array is the distinction between Premium to Discount inside that
dealing range including the array list inside the two ranges. Dealing range is the new trading range formed after buyside and sale side
is taken.
PD array is the distinction between Premium to Discount inside that
dealing range including the array list inside the two ranges. Dealing range is the new trading range formed after buyside and sale side
is taken.
PD array is the distinction between Premium to Discount inside that
dealing range including the array list inside the two ranges. Dealing range is the new trading range formed after buyside and sale side
is taken.
PD array is the distinction between Premium to Discount inside that
dealing range including the array list inside the two ranges. Dealing range is the new trading range formed after buyside and sale side
is taken.
PD array is the distinction between Premium to Discount inside that
dealing range including the array list inside the two ranges. Dealing range is the new trading range formed after buyside and sale side
is taken.
PD array is the distinction between Premium to Discount inside that
dealing range including the array list inside the two ranges. Dealing range is the new trading range formed after buyside and sale side
is taken.
PD array is the distinction between Premium to Discount inside that
dealing range including the array list inside the two ranges. Dealing range is the new trading range formed after buyside and sale side
is taken.
PD array is the distinction between Premium to Discount inside that
dealing range including the array list inside the two ranges. Dealing range is the new trading range formed after buyside and sale side
is taken.
PD array is the distinction between Premium to Discount inside that
dealing range including the array list inside the two ranges. Dealing range is the new trading range formed after buyside and sale side
is taken.
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
how to sell pi coins in all Africa Countries.DOT TECH
Yes. You can sell your pi network for other cryptocurrencies like Bitcoin, usdt , Ethereum and other currencies And this is done easily with the help from a pi merchant.
What is a pi merchant ?
Since pi is not launched yet in any exchange. The only way you can sell right now is through merchants.
A verified Pi merchant is someone who buys pi network coins from miners and resell them to investors looking forward to hold massive quantities of pi coins before mainnet launch in 2026.
I will leave the telegram contact of my personal pi merchant to trade with.
@Pi_vendor_247
National Financial Reporting Authority (NFRA)enjoydebbarma13
National Financial Reporting Authority (NFRA) is an independent regulator set up to overseas the auditing profession and accounting standard in India under the Companies Act 2013.
US Economic Outlook - Being Decided - M Capital Group August 2021.pdfpchutichetpong
The U.S. economy is continuing its impressive recovery from the COVID-19 pandemic and not slowing down despite re-occurring bumps. The U.S. savings rate reached its highest ever recorded level at 34% in April 2020 and Americans seem ready to spend. The sectors that had been hurt the most by the pandemic specifically reduced consumer spending, like retail, leisure, hospitality, and travel, are now experiencing massive growth in revenue and job openings.
Could this growth lead to a “Roaring Twenties”? As quickly as the U.S. economy contracted, experiencing a 9.1% drop in economic output relative to the business cycle in Q2 2020, the largest in recorded history, it has rebounded beyond expectations. This surprising growth seems to be fueled by the U.S. government’s aggressive fiscal and monetary policies, and an increase in consumer spending as mobility restrictions are lifted. Unemployment rates between June 2020 and June 2021 decreased by 5.2%, while the demand for labor is increasing, coupled with increasing wages to incentivize Americans to rejoin the labor force. Schools and businesses are expected to fully reopen soon. In parallel, vaccination rates across the country and the world continue to rise, with full vaccination rates of 50% and 14.8% respectively.
However, it is not completely smooth sailing from here. According to M Capital Group, the main risks that threaten the continued growth of the U.S. economy are inflation, unsettled trade relations, and another wave of Covid-19 mutations that could shut down the world again. Have we learned from the past year of COVID-19 and adapted our economy accordingly?
“In order for the U.S. economy to continue growing, whether there is another wave or not, the U.S. needs to focus on diversifying supply chains, supporting business investment, and maintaining consumer spending,” says Grace Feeley, a research analyst at M Capital Group.
While the economic indicators are positive, the risks are coming closer to manifesting and threatening such growth. The new variants spreading throughout the world, Delta, Lambda, and Gamma, are vaccine-resistant and muddy the predictions made about the economy and health of the country. These variants bring back the feeling of uncertainty that has wreaked havoc not only on the stock market but the mindset of people around the world. MCG provides unique insight on how to mitigate these risks to possibly ensure a bright economic future.
USDA Loans in California: A Comprehensive Overview.pptxmarketing367770
USDA Loans in California: A Comprehensive Overview
If you're dreaming of owning a home in California's rural or suburban areas, a USDA loan might be the perfect solution. The U.S. Department of Agriculture (USDA) offers these loans to help low-to-moderate-income individuals and families achieve homeownership.
Key Features of USDA Loans:
Zero Down Payment: USDA loans require no down payment, making homeownership more accessible.
Competitive Interest Rates: These loans often come with lower interest rates compared to conventional loans.
Flexible Credit Requirements: USDA loans have more lenient credit score requirements, helping those with less-than-perfect credit.
Guaranteed Loan Program: The USDA guarantees a portion of the loan, reducing risk for lenders and expanding borrowing options.
Eligibility Criteria:
Location: The property must be located in a USDA-designated rural or suburban area. Many areas in California qualify.
Income Limits: Applicants must meet income guidelines, which vary by region and household size.
Primary Residence: The home must be used as the borrower's primary residence.
Application Process:
Find a USDA-Approved Lender: Not all lenders offer USDA loans, so it's essential to choose one approved by the USDA.
Pre-Qualification: Determine your eligibility and the amount you can borrow.
Property Search: Look for properties in eligible rural or suburban areas.
Loan Application: Submit your application, including financial and personal information.
Processing and Approval: The lender and USDA will review your application. If approved, you can proceed to closing.
USDA loans are an excellent option for those looking to buy a home in California's rural and suburban areas. With no down payment and flexible requirements, these loans make homeownership more attainable for many families. Explore your eligibility today and take the first step toward owning your dream home.
USDA Loans in California: A Comprehensive Overview.pptx
bristol myerd squibb Deutsche Bank Securities Inc. Health Care Conference
1. Lamberto Andreotti
Executive Vice President
&
Chief Operating Officer
Deutsche Bank Healthcare Conference
May 7, 2008
This presentation is intended solely for an investment community/industry audience-not for promotional use
community/industry audience-
2. May 7, 2008
During this meeting, we will make statements about the Company’s future
plans and prospects, including statements about our financial position,
business strategy, research pipeline concerning product development and
product potential, that constitute forward-looking statements for purposes
of the safe harbor provisions under the Private Securities Litigation Reform
Act of 1995.
Actual results may differ materially from those indicated by these forward-
looking statements as a result of various important factors, including those
discussed in the company’s most recent annual report on Form 10-K,
periodic reports on Form 10-Q and current reports on Form 8-K. These
documents are available from the SEC, the Bristol-Myers Squibb website
or from Bristol-Myers Squibb Investor Relations.
In addition, any forward-looking statements represent our estimates only as
of today and should not be relied upon as representing our estimates as of
any subsequent date. While we may elect to update forward-looking
statements at some point in the future, we specifically disclaim any
obligation to do so, even if our estimates change.
This presentation is intended solely for an investment community/industry audience-not for promotional use
community/industry audience-
3. Next Generation BioPharma
Best of Pharma
Best of Biotech
Next Generation
BioPharma
Selectively
Innovative Continuous
Integrated
Portfolio Improvement
Business Model
Agile, Entrepreneurial and Accountable Culture
This presentation is intended solely for an investment community/industry audience-not for promotional use
community/industry audience- 3
4. Q1 2008 Performance
Strong underlying sales growth +9%
Gross and operating margin improvement
Non-GAAP EPS of $0.42 vs. $0.36 Q1 2007
Decision to retain Mead Johnson within
business portfolio
Recent announcement to sell ConvaTec
Confirmed 3 year non-GAAP guidance
All GAAP to non-GAAP reconciliations are available on our website.
This presentation is intended solely for an investment community/industry audience-not for promotional use
community/industry audience- 4
5. Q1 2008 Sales: Growth Brands
$1,400
$1,308
+39%
$1,200
$1,000
$800
$M
$600
$454
$400 +24% $297
$305 $273
$187
+13% +13% +21%
$200
+17%
$0
Plavix Abilify Avapro Reyataz Sustiva Erbitux
This presentation is intended solely for an investment community/industry audience-not for promotional use
community/industry audience- 5
6. Q1 2008 Sales: New Products
$120
$108
+140%
$100
$87
$80 +112%
$66
$M $60 +314%
$40
$25
$20
$0
Baraclude Orencia Sprycel Ixempra
This presentation is intended solely for an investment community/industry audience-not for promotional use
community/industry audience- 6
7. Plavix Indications
Potential Patient
Proven Efficacy
and Safety Population ~49 million
Indicated for use in broad
patient population Other CV
~28 million
Efficacy and safety of ACS / Stent
Plavix well understood ~1.5 million
ACS
PAD Stroke
Increased hospital
~3 million
~8 million ~10 million
resources focused
on risk benefit ACS / Non-Stent
~1.5 million
Growth opportunities
within ACS as well as
stroke and PAD
This presentation is intended solely for an investment community/industry audience-not for promotional use
community/industry audience- 7
8. Abilify – Broad Clinical Profile and
Specialty Execution
Q1 global sales up 24%
Broadest set of indications for any atypical
US approval in major depressive disorder
EU approval for bipolar mania
Succesful DTC campaign
This presentation is intended solely for an investment community/industry audience-not for promotional use
community/industry audience- 8
9. Orencia – Goal to Become
the IV Biologic of Choice
Q1 sales $87 million +112%
Focus on efficacy and durability of response
Recent label change broadening indication
regardless of prior treatment
Promotional programs focused on
compliance and persistence
DTC campaign focused on defining
inadequate response
This presentation is intended solely for an investment community/industry audience-not for promotional use
community/industry audience- 9
10. Our Productivity Approach
Management Council
Productivity Transformation Team
Supply Chain R&D G&A
Commercial
Operations
$400 MM $200 MM $550 MM $350 MM
$1.5 Billion
Cost Savings + Cost Avoidance
This presentation is intended solely for an investment community/industry audience-not for promotional use
community/industry audience- 10
11. Supply Chain Redesigned to Support
BioPharma Model
Strategic Filters
Current 2011
27 Plants >50% Reduction
Future Geographic Product
Portfolio Footprint Rationalization
Network segmented and specialized
In-house Biologics capability
Aggressive outsourcing of mature products
Generating $400 Million in Productivity
This presentation is intended solely for an investment community/industry audience-not for promotional use
community/industry audience- 11
12. Customer Model Restructured
to Support BioPharma
12,000
Primary Care
10,000
Specialty
8,000 Field-Based Medical
FTEs
Total Field Force
6,000
4,000
2,000
0
2005 2006 2007 2008
Specialty Model synergizes Sales Force and Field-Based
Medical experts
Partnering on Primary Care maximizes capacity and
capability while minimizing fixed overhead
Increasing productivity
This presentation is intended solely for an investment community/industry audience-not for promotional use
community/industry audience- 12
13. Key 2008 Events
ASCO
– Erbitux FLEX data
– Sprycel phase II prostate data
– Ipilimumab data
ADA
– Saxagliptin phase III data
– Dapaglifozin phase IIb data
EASD
– Saxagliptin phase III data
ASH
– Apixiban phase III data
This presentation is intended solely for an investment community/industry audience-not for promotional use
community/industry audience- 13
14. Next Generation BioPharma
Best of Pharma
Best of Biotech
Next Generation
BioPharma
Selectively
Innovative Continuous
Integrated
Portfolio Improvement
Business Model
Agile, Entrepreneurial and Accountable Culture
This presentation is intended solely for an investment community/industry audience-not for promotional use
community/industry audience- 14
15. Lamberto Andreotti
Executive Vice President
&
Chief Operating Officer
Deutsche Bank Healthcare Conference
May 7, 2008
This presentation is intended solely for an investment community/industry audience-not for promotional use
community/industry audience-